Advancing AAV vector manufacturing: challenges, innovations, and future directions for gene therapy

Area of Science:

• Biotechnology and Gene Therapy Manufacturing

Background:

• Adeno-Associated Virus (AAV) vectors are crucial for gene therapy but face manufacturing hurdles like variability, low yields, and scalability issues.
• Current manufacturing processes require optimization to meet the growing demand for AAV-based therapeutics.

Purpose of the Study:

• To provide a comprehensive framework for robust Adeno-Associated Virus (AAV) gene therapy manufacturing.
• To evaluate industry challenges and recent technological innovations in AAV production.

Main Methods:

• Review of end-to-end AAV manufacturing processes, including upstream (cell culture, transfection) and downstream (purification, fill-finish) operations.
• Analysis of key innovations such as high-density perfusion cultures, advanced plasmid systems, next-generation transfection reagents, and improved chromatographic techniques.
• Emphasis on the Quality-by-Design (QbD) framework, process characterization, scale-down models, and Design of Experiments (DoE).

Main Results:

• Upstream innovations enhance process quality and viral vector productivity.
• Downstream advancements improve the separation of full and empty AAV capsids.
• A Quality-by-Design framework, supported by rigorous process characterization and DoE, is essential for robust control strategies, process validation, and regulatory compliance.

Conclusions:

• Implementing advanced technologies and a Quality-by-Design approach is critical for overcoming AAV manufacturing challenges.
• Integration of artificial intelligence and continuous manufacturing will accelerate the development of safer, more effective, and personalized AAV gene therapies.